KPV
Last reviewed 2026-10-30
Our read Opinion
Evidence remains preclinical, including mouse colitis models. FDA moved KPV to its withdrawn-nomination table; this is not authorization for compounding.
- Type
- Research-only / unapproved
- Regulatory status
- Not FDA-approved; no verified marketing authorization
- Compounding status
- Off Category 2, review pending
- FDA-approved indications
- None
- Evidence level
- Animal studies mostly
- Routes studied
- Oral, Topical
- WADA
- Verify
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to support gut lining repair
- —Claimed to calm inflammation
Lys-Pro-Val is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. In cell and mouse models, PepT1-mediated uptake inhibits inflammatory NF-kappaB and MAPK signaling.
Not FDA-approved; no foreign marketing authorization was verified. FDA reports no identified human exposure data for KPV drug products and insufficient information to assess harm.
Statuses change; check the linked primary source.
Momentum Opinion
Rising
0 news items in last 30 days
Mechanistic plausibility is not evidence that KPV treats human bowel or skin disease. Human safety and controlled efficacy studies are the missing steps.
No news yet for this peptide.
Gut lining repair and calmer inflammation for IBS/IBD-type symptoms and 'leaky gut'.
Whole-body repair: injury healing plus gut lining support, skin and hair quality, and lower inflammation.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.